Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,030JPY
9:32pm EDT
Change (% chg)

¥10 (+0.50%)
Prev Close
¥2,020
Open
¥2,043
Day's High
¥2,050
Day's Low
¥2,029
Volume
477,300
Avg. Vol
1,224,585
52-wk High
¥2,087
52-wk Low
¥1,412

Latest Key Developments (Source: Significant Developments)

Arqule trial did not meet its primary endpoint of progression free survival
Monday, 27 Mar 2017 07:00am EDT 

Arqule Inc : Trial did not meet its primary endpoint of progression free survival (pfs). . There were no new safety issues observed in trial .Its partner, Kyowa Hakko Kirin, announced top-line results of JET-HCC phase 3 trial of Tivantinib in Japan.  Full Article

Kyowa Hakko Kirin sets up KYOWA KIRIN FRONTIER Co., Ltd.
Wednesday, 1 Feb 2017 12:16am EST 

Kyowa Hakko Kirin Co Ltd <4151.T>: Says it set up KYOWA KIRIN FRONTIER Co., Ltd. .Says the capital is 100 million yen.  Full Article

R&I affirms Kyowa Hakko Kirin Co Ltd's rating at "A+" and announces stable outlook -R&I
Monday, 22 Aug 2016 02:14am EDT 

Kyowa Hakko Kirin Co Ltd <4151.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I .Rating outlook stable.  Full Article

Medgenics enters collaboration with Kyowa Hakko Kirin
Monday, 6 Jun 2016 07:00am EDT 

Medgenics Inc : Entered collaboration with Kyowa Hakko Kirin Co Ltd for development and commercialization of Kyowa Hakko's anti-light monoclonal antibody . Data from signal finding study in severe pediatric onset inflammatory bowel disease patients expected in first half 2017 . Upon completion of signal finding study in severe pediatric onset IBD, company will have option to license rights to develop program . Following exercise of option, medgenics will make a one-time, upfront payment in low single-digit millions to Kyowa Hakko Kirin .Co to have commercialization rights in U.S., Canada, will also add rights in europe if Kyowa Hakko Kirin selects licensing arrangement.  Full Article

Kyowa Hakko Kirin raises consolidated mid-year and full-year outlook for FY 2015
Friday, 24 Jul 2015 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:Says the company raised the consolidated mid-year outlook for the FY ending Dec. 2015.Revenue forecast increased to 178,800 million yen from 172,000 million yen.Operating profit forecast increased to 22,400 million yen from 16,500 million yen.Says the company raised the consolidated full-year outlook for the FY ending Dec. 2015.Revenue forecast increased to 360,000 million yen from 354,000 million yen.Operating profit forecast increased to 47,000 million yen from 41,500 million yen.Ordinary profit forecast increased to 41,000 million yen from 34,000 million yen.Net profit forecast increased to 26,000 million yen from 18,500 million yen.Earnings per share forecast increased to 47.51 yen from 33.80 yen.Comments that increased sales and decreased investment loss and corporate tax are the main reasons for the forecast.  Full Article

Kyowa Hakko Kirin announces Fujifilm Kyowa Kirin Biologics establishes joint venture with AstraZeneca to develop and commercialise anti-VEGF biosimilar
Friday, 24 Jul 2015 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:Fujifilm Kyowa Kirin Biologics has entered into an agreement with AstraZeneca plc to establish a joint venture in UK for the development and commercialisation of FKB238 in development for the treatment of multiple solid tumours.Fujifilm Kyowa Kirin Biologics and AstraZeneca to hold 50 pct stake in the JV respectively, and the JV with registered capital of $90 mln.  Full Article

R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook
Thursday, 16 Jul 2015 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+".Rating outlook stable.  Full Article

More From Around the Web

BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab

* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia